These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 20606323)
1. Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. Ohtsuki S; Yamaguchi H; Kang YS; Hori S; Terasaki T Biol Pharm Bull; 2010; 33(7):1250-2. PubMed ID: 20606323 [TBL] [Abstract][Full Text] [Related]
2. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Boado RJ; Li JY; Nagaya M; Zhang C; Pardridge WM Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12079-84. PubMed ID: 10518579 [TBL] [Abstract][Full Text] [Related]
3. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Kageyama T; Nakamura M; Matsuo A; Yamasaki Y; Takakura Y; Hashida M; Kanai Y; Naito M; Tsuruo T; Minato N; Shimohama S Brain Res; 2000 Oct; 879(1-2):115-21. PubMed ID: 11011012 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. Boado RJ; Li JY; Tsukamoto H; Pardridge WM J Neurochem; 2003 May; 85(4):1037-42. PubMed ID: 12716435 [TBL] [Abstract][Full Text] [Related]
5. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease. Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060 [TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes. Gynther M; Puris E; Peltokangas S; Auriola S; Kanninen KM; Koistinaho J; Huttunen KM; Ruponen M; Vellonen KS Pharm Res; 2018 Nov; 36(1):17. PubMed ID: 30488131 [TBL] [Abstract][Full Text] [Related]
7. l-Citrulline restores nitric oxide level and cellular uptake at the brain capillary endothelial cell line (TR-BBB cells) with glutamate cytotoxicity. Lee KE; Kang YS Microvasc Res; 2018 Nov; 120():29-35. PubMed ID: 29870781 [TBL] [Abstract][Full Text] [Related]
8. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. Sconce MD; Churchill MJ; Greene RE; Meshul CK Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Kanagaraj N; Beiping H; Dheen ST; Tay SS Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of Lee KE; Kang YS J Biomed Sci; 2017 May; 24(1):28. PubMed ID: 28490336 [TBL] [Abstract][Full Text] [Related]
11. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. Boado RJ; Li JY; Pardridge WM J Neurochem; 2003 Mar; 84(6):1322-31. PubMed ID: 12614332 [TBL] [Abstract][Full Text] [Related]
12. Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model. Zhang Y; He X; Meng X; Wu X; Tong H; Zhang X; Qu S Cell Death Dis; 2017 Feb; 8(2):e2574. PubMed ID: 28151476 [TBL] [Abstract][Full Text] [Related]
13. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine. Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940 [TBL] [Abstract][Full Text] [Related]
14. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503 [TBL] [Abstract][Full Text] [Related]
15. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429 [TBL] [Abstract][Full Text] [Related]
16. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Takahashi Y; Nishimura T; Higuchi K; Noguchi S; Tega Y; Kurosawa T; Deguchi Y; Tomi M Pharm Res; 2018 Oct; 35(12):246. PubMed ID: 30374619 [TBL] [Abstract][Full Text] [Related]
17. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice. Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172 [TBL] [Abstract][Full Text] [Related]
18. Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Boado RJ; Li JY; Pardridge WM Pediatr Res; 2004 Apr; 55(4):557-60. PubMed ID: 14764922 [TBL] [Abstract][Full Text] [Related]
19. Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Bélanger M; Asashima T; Ohtsuki S; Yamaguchi H; Ito S; Terasaki T Neurochem Int; 2007 Jan; 50(1):95-101. PubMed ID: 16956696 [TBL] [Abstract][Full Text] [Related]
20. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Matsuo H; Tsukada S; Nakata T; Chairoungdua A; Kim DK; Cha SH; Inatomi J; Yorifuji H; Fukuda J; Endou H; Kanai Y Neuroreport; 2000 Nov; 11(16):3507-11. PubMed ID: 11095508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]